Neurogene Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $925,000 | $0 | — | — |
| Research and development | $75.0M | $60.9M | $44.4M | $47.5M | $39.2M |
| Operating expenses | $103.3M | $83.5M | $55.6M | $56.5M | $60.7M |
| Operating income | -$103.3M | -$82.6M | -$55.6M | -$56.5M | -$60.7M |
| Interest expense | $5,000 | $12,000 | $12,000 | $2,000 | — |
| Pretax income | -$90.4M | -$75.1M | -$36.3M | -$55.2M | -$60.7M |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$90.4M | -$75.1M | -$36.3M | -$55.2M | -$60.7M |
| Balance Sheet | |||||
| Cash and equivalents | $103.8M | $136.6M | $148.2M | $82.0M | $142.5M |
| Current assets | $271.8M | $315.9M | $200.3M | $84.7M | $144.0M |
| Total assets | $288.6M | $335.7M | $222.6M | $109.3M | $163.3M |
| Current liabilities | $16.4M | $15.2M | $23.0M | $6.7M | $8.6M |
| Total liabilities | $23.7M | $25.4M | $36.5M | $10.6M | $20.4M |
| Stockholders' equity | $264.9M | $310.4M | $186.0M | -$145.7M | -$91.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$77.2M | -$70.6M | -$51.4M | -$52.8M | -$47.6M |
| Depreciation and amortization | $3.0M | $3.2M | $3.3M | $3.2M | $1.3M |
| Stock-based compensation | $14.2M | $8.3M | $1.4M | $1.3M | $11.6M |
| Capital expenditure | $1.2M | $808,000 | $321,000 | $2.2M | $3.3M |
| Free cash flow | -$78.4M | -$71.4M | -$51.7M | -$55.1M | -$50.8M |
| Impairments | $120,000 | $91,000 | $0 | $0 | — |
Shares outstanding 15.8M · Free float 45.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.